Product Wiki · Recalls · EU Safety Gate (RAPEX)

Gouaches aux doigts — recall A12/03374/24

EU Safety Gate (RAPEX) · France · 2024-12-06 · Serious risk

Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked on this page. No AI-generated text appears on this page. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/03374/24
Date of alert
2024-12-06
Country / jurisdiction
France
Risk level
Serious risk
Risk type
Chemical
Brand
Mes belles couleurs
Product category
Toys
Product type
Finger paint
Barcode (EAN/GTIN)
3760002573915
Reported risk: The white, blue, red and black paintings have an excessive concentration of methylisothiazolinone (MI)(measured values: up to 2.8 mg/kg). MI causes severe skin burns and eye damage (if in contact with the eyes), and may cause an allergic skin reaction. In addition, the green painting has an excessive concentration of formaldehyde (measured value: 0.25 mg/kg). Formaldehyde is a skin sensitiser and can trigger allergic reactions and may cause cancer.
What to do

Check whether your product matches this notice (name, batch, dates). If it does, stop using it and follow the instructions in the official notice — refund, return, repair or disposal are set by the issuing authority and the business, and they differ per recall. Official notice from EU Safety Gate (RAPEX) →

Action taken by the authority
Type of economic operator taking notified measure
Retailer
Category of measure
Recall of the product from end users
Date of entry into force
30/09/2024
Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10092180

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.